These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33640861)

  • 1. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
    Arnaud A; Suthoff E; Stenson K; Werneburg B; Hodgkins P; Bonthapally V; Jonas J; Meyer K; O'Day K
    J Affect Disord; 2021 Apr; 285():112-119. PubMed ID: 33640861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
    Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
    Meshkat S; Teopiz KM; Di Vincenzo JD; Bailey JB; Rosenblat JD; Ho RC; Rhee TG; Ceban F; Kwan ATH; Cao B; McIntyre RS
    J Affect Disord; 2023 Nov; 340():893-898. PubMed ID: 37557991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
    Clayton AH; Lasser R; Parikh SV; Iosifescu DV; Jung J; Kotecha M; Forrestal F; Jonas J; Kanes SJ; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):676-684. PubMed ID: 37132201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
    Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
    Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials.
    Lian J; Lin Z; Li X; Chen G; Wu D
    J Affect Disord; 2024 Jun; 354():206-215. PubMed ID: 38479510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Chalet FX; Luyet PP; Rabasa C; Vaillant C; Saskin P; Ahuja A; Citrome L
    Postgrad Med; 2024 May; 136(4):396-405. PubMed ID: 38814132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
    Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
    J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA; Cucchiaro J; Loebel A
    J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
    Parikh SV; Aaronson ST; Mathew SJ; Alva G; DeBattista C; Kanes S; Lasser R; Bullock A; Kotecha M; Jung J; Forrestal F; Jonas J; Vera T; Leclair B; Doherty J
    Neuropsychopharmacology; 2024 Jan; 49(2):467-475. PubMed ID: 37875578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zuranolone and its role in treating major depressive disorder: a narrative review.
    Ali M; Ullah I; Diwan MN; Aamir A; Awan HA; Waris Durrani A; Qudrat QU; Shoib S; De Berardis D
    Horm Mol Biol Clin Investig; 2023 Jun; 44(2):229-236. PubMed ID: 36848317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis.
    Ahmad A; Awan AR; Nadeem N; Javed AS; Farooqi M; Daniyal M; Mumtaz H
    Front Neurosci; 2024; 18():1361692. PubMed ID: 38726035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Matsunaga S; Iwata N
    Eur Arch Psychiatry Clin Neurosci; 2017 Mar; 267(2):149-161. PubMed ID: 27318835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
    Vázquez GH; Bahji A; Undurraga J; Tondo L; Baldessarini RJ
    J Psychopharmacol; 2021 Aug; 35(8):890-900. PubMed ID: 34238049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Goldberg JF; Portland KB
    J Affect Disord; 2013 Nov; 151(2):409-417. PubMed ID: 23890583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
    Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
    J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.